The DEA Isn't Banning Kratom. It's Going After the Products Designed to Act Like an Opioid.

A gas-station shot bottle and a cup of traditional kratom tea are not the same product, and the DEA’s newest move finally draws that line in federal law instead of leaving it to the label. On July 1, 2026, the DEA filed a Notice of Intent to temporarily place concentrated 7-hydroxymitragynine — known in the industry as 7-OH — into Schedule I, alongside three synthetic derivatives that don’t occur naturally in the kratom plant at all. HHS and the FDA moved fast to back the action, framing high-concentration 7-OH products as functionally opioid-like: they bind the same receptors, produce similar euphoria and sedation, and carry a real overdose and dependence risk that the kratom leaf itself, at natural concentrations, does not.

Kratom leaf and tea contain 7-OH too, but at far lower levels than the tablets, shots, and extracts the FDA has spent the past year warning about in a public campaign it titled, bluntly, “Hiding in Plain Sight.” That’s the plain-language version of a genuinely confusing regulatory moment: this is not the kratom ban that’s been rumored and fought over for a decade. The DEA’s Notice of Intent explicitly carves out the kratom plant and low-concentration derivatives, leaving them unscheduled under federal law, while targeting only the products engineered to concentrate 7-OH above a specific threshold — the ones marketed less like an herbal tea and more like a legal opioid substitute sold next to the energy drinks.

For treatment providers, the useful distinction isn’t legal, it’s clinical: a patient who mentions “kratom” could mean an occasional cup of tea, or could mean a daily habit built on concentrated extract shots with a withdrawal profile that looks a lot like opioid withdrawal — and those two patients need very different conversations. The Congressional Research Service’s legal sidebar on the scheduling action is worth the ten minutes if you’re building an intake script this fall; a temporary Schedule I order under the Controlled Substances Act typically runs up to three years while a permanent scheduling process plays out, which means the products your patients can legally buy could change again before this is finalized.

What doesn’t change in the meantime: someone dependent on high-dose 7-OH extract is dependent on something that acts like an opioid on their brain, whatever the label says, and a hard stop without medical support carries real withdrawal risk. That’s worth naming to a patient plainly, not as a scare tactic — as the same harm-reduction honesty you’d want if it were any other opioid-like substance in the room.